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Abstract
The complexities and heterogeneity of the ageing process have slowed the development of consensus on appropriate bio-
markers of healthy ageing. The MRC-Arthritis Research UK Centre for Integrated research into Musculoskeletal Ageing
(CIMA) is a collaboration between researchers and clinicians at the Universities of Liverpool, Sheffield and Newcastle. One
of CIMA’s objectives is to ‘Identify and share optimal techniques and approaches to monitor age-related changes in all mus-
culoskeletal tissues, and to provide an integrated assessment of musculoskeletal function’, i.e. to develop a toolkit for asses-
sing musculoskeletal ageing. This toolkit is envisaged as an instrument that can be used to characterise and quantify
musculoskeletal function during ‘normal’ ageing, lend itself to use in large-scale, internationally important cohorts, and pro-
vide a set of biomarker outcome measures for epidemiological and intervention studies designed to enhance healthy muscu-
loskeletal ageing. Such potential biomarkers include: biochemical measurements in biofluids or tissue samples, in vivo
measurements of body composition, imaging of structural and physical properties, and functional tests. The CIMA Toolkit
Working Group assessed candidate biomarkers of musculoskeletal ageing under these four headings, detailed their biological
bases, strengths and limitations, and made practical recommendations for their use. In addition, the CIMA Toolkit Working
Group identified gaps in the evidence base and suggested priorities for further research on biomarkers of musculoskeletal
ageing.
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Ageing is associated with the accumulation of damage to all
the macromolecules within and outside cells leading to pro-
gressively more cellular and tissue defects and resulting in
age-related frailty, disability and disease [1]. There is sub-
stantial inter-individual variability in the ageing process, so
that biological age can differ considerably from chrono-
logical age [2]. However, the complexities and heterogene-
ities of the ageing process have made it difficult to define
and to measure ageing, and this has slowed the develop-
ment of consensus on appropriate biomarkers of ageing
generically and for ageing of specific organs and tissues.
Although the need has been identified [3], to date there
appears to have been no attempt to develop a specific set
of biomarkers of ageing of the musculoskeletal system.
This Commentary provides an executive summary of a pro-
posed toolkit for assessing musculoskeletal ageing which is
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published in full as a supplement to Age and Ageing [4].
This toolkit was developed by The MRC-Arthritis Research
UK Centre for Integrated research into Musculoskeletal
Ageing (CIMA)1 which is a collaboration between research-
ers and clinicians at the Universities of Liverpool, Sheffield
and Newcastle.
Towards a toolkit for assessing
musculoskeletal ageing
One of CIMA’s objectives is to ‘identify and share optimal
techniques and approaches to monitor age-related changes
in all musculoskeletal tissues, and to provide an integrated
assessment of musculoskeletal function’, i.e. to develop a
toolkit for assessing musculoskeletal ageing. To address this
objective, CIMA established a Toolkit Working Group and
held a workshop with a panel of experts from UK and
European institutions with well-established track records of
research into musculoskeletal ageing. Workshop participants
were tasked with defining a framework for the selection of
biomarkers of ageing that are relevant to the multiple tissues
of the musculoskeletal system, are distinct from markers of
disease, change with age, and are sensitive to intervention.
The ambitions for the toolkit are that it should: characterise
and quantify musculoskeletal function over multiple dec-
ades, i.e. during ‘normal’ ageing, facilitate epidemiological
assessment of musculoskeletal decline, provide a set of out-
come measures for intervention studies (using, e.g. drugs or
lifestyle) designed to enhance healthy musculoskeletal ageing
and become the protocol of choice, adopted by multiple
large-scale, internationally important cohorts. Candidate bio-
markers were considered under four headings:
• Biochemical biomarkers
• Body composition biomarkers
• Imaging assessments
• Functional assessments
Biochemical biomarkers of musculoskeletal
ageing
Biochemical biomarkers are markers measurable in situ or
ex vivo in biofluid samples and tissue biopsies that are pro-
duced in, or released from, a tissue and that are specific for
a characteristic process or cell in that tissue. Two well-
established serum markers of bone turnover were recom-
mended for the toolkit i.e. N-terminal propeptide of type I
procollagen (PINP) and C-terminal cross-linked telopeptide
of collagen type I (CTX, also known as CTX-I). Five fur-
ther markers of bone turnover viz. osteocalcin; bone
alkaline phosphatase; N-terminal cross-linked telopeptide of
collagen type I (NTX); carboxy-terminal cross-linked
telopeptide of type I collagen generated by matrix metallo-
proteinases (ICTP); and tartrate-resistant acid phosphatase
isoform 5b (TRACP5b) are potential future candidates.
Urinary type II collagen C-telopeptide fragment (CTX-II)
and serum cartilage oligomeric matrix protein (COMP) are
two possible biomarkers of cartilage ageing but they have
not been shown to be reliable markers of collagen ageing
per se, independent of osteoarthritis. Serum creatinine may
be a reliable biomarker of skeletal muscle mass (with appro-
priate dietary control). Potential next generation muscle bio-
chemical biomarkers include: 3-methylhistidine, type VI
collagen, the N-terminal peptide of procollagen type III
(P3NP), agrin and growth differentiation factors.
Body composition biomarkers
Body composition changes during development and ageing,
and such changes are linked with changes in function and in
the risk of age-related musculoskeletal disease. The CIMA
Toolkit Working Group recommended the use of dual-
energy X-ray absorptiometry (DXA) which remains the
most widely recommended method for diagnosing sarcope-
nia (age-associated loss of muscle mass) as a stand-alone
measure or as part of the screening procedure for sarcope-
nia and is also recommended by the European Working
Group on Sarcopenia in Older People (EWGSOP) [5].
Other in vivo imaging techniques including ultrasound and
magnetic resonance imaging have been used to measure
bone and muscle volume (as a surrogate for mass) and the
size of musculoskeletal structures (such as cartilage thick-
ness), and with further development and validation may
offer the ability to assess musculoskeletal tissue structure
(e.g. muscle pennation).
Functional assessments
Functional assessments test the workings of the integrated
musculoskeletal system which has the advantage of direct
relevance to clinical state and quality of life, for which sys-
tem integration is important. The CIMA Toolkit Working
Group recognised that there are several well-established
functional assessment tools including the short physical per-
formance battery (SPPB) and the locomotor domain of the
NIH toolbox for assessment of neurological and behav-
ioural function [6]. While valid and reliable tests of balance
are available, and have been shown to be associated with
muscle function, balance control is affected by factors other
than musculoskeletal ageing per se. In addition, it is unclear
whether balance problems precede decreases in muscle
function. To date there is no fully validated system for real-
life monitoring of musculoskeletal function but, in the
future, low-cost body-worn movement monitors may offer
an affordable and scalable solution for quantitative gait
evaluation in both multicentre studies and real-world set-
tings [7].
Conclusions and future perspectives
Progress in developing and validating biomarkers of muscu-
loskeletal ageing in humans has been slow and uneven and,1 http://www.cimauk.org/
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to date, there are relatively few accepted and reliable biomar-
kers for ageing of this major body system. Recommendations
for biomarkers of musculoskeletal ageing proposed by the
CIMA Toolkit Working Group are summarised in Table 1.
For bones and muscle, there useful biomarkers of age-
ing, but for the other components of the musculoskeletal
system—tendons and joints—no such biomarkers are cur-
rently available. However, measures of physical capability
have the advantage that, to a considerable extent, they
reflect function of the integrated musculoskeletal system.
This slow progress in developing biomarkers of musculo-
skeletal ageing parallels the situation with biomarkers of
ageing per se [8–10], and reflects both the complexity and
heterogeneity of ageing, and the difficulties in distinguishing
between biomarkers of an ageing body system and biomar-
kers of age-related disease in that system.
Research priorities and future development
of the toolkit
This review reveals that much research effort has been
devoted to disease-related biomarkers, and relatively little to
biomarkers of musculoskeletal ageing itself. There are both
conceptual and practical reasons for this imbalance in
research focus, and the problems are amplified at older
ages when multi-morbidity and polypharmacy are more
common [11]. This suggests that research on biomarkers of
musculoskeletal ageing is likely to be more rewarding if it is
conducted earlier in the ageing trajectory. Success in the
search for reliable biomarkers of musculoskeletal ageing will
require innovation, not only in the application of new tech-
nologies and emerging understanding of the biology of the
ageing process, but also in experimental design. There may
be merit in the study of individual trajectories in musculo-
skeletal function during middle age, in advance of the dis-
ability and disease (including non-musculoskeletal diseases)
that are likely to be major confounders. This will require
repeated measures of musculoskeletal function, appropriate
imaging and collection of biological samples for biomarker
assessment at more frequent intervals than is usual in large
ageing cohorts. In addition, measurement tools will need to
be much more sensitive to detect the subtler age-related
changes that are characteristic of the ageing phenotype.
We anticipate that further development of the CIMA
Toolkit will include new biomarkers emerging from
molecular investigation of musculoskeletal ageing. These
may include DNA methylation other epigenetic-based bio-
markers particularly those based on non-coding RNA spe-
cies [12]. In the associated Supplement [4], we have
summarised progress in identification of microRNA which
are linked with risk of osteoporosis, and which may be bio-
markers of joint ageing more generally. Recently, differential
expression of a number of small nucleolar RNAs
(snoRNA; another group of non-coding, regulatory RNA)
in young versus old and normal versus OA murine joints
and serum has been described, which suggests that
snoRNA are also putative markers of musculoskeletal age-
ing [13]. In addition, a wide range of biological approaches,
including proteomics and metabolomics [14], are being
used to identify and validate biomarkers of ageing [15],
some of which may be applicable to the musculoskeletal
system.
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